Recently, we acquired Cellesce Ltd (Cellesce) which specializes in contract development and manufacturing of large scale patient-derived organoids (PDOs) for diverse applications, including drug screening.

Following our acquisition of Cellesce Ltd, Tanya Samazan from Instrument Business Outlook dove deep into conversation with our President Susan Murphy and Cellesce CEO Vicky Marsh-Durban about how their complementary expertise and technologies will accelerate organoid research.

We are pleased to announce our collaboration with Advanced Solutions Life Sciences to develop 3D biology automation technologies for drug discovery.

Under this partnership, we will commercialize the BioAssemblyBot 400 (BAB400) for Drug Discovery. Jointly developed by experts from both companies, the BAB400 for Drug Discovery includes specific enhancements to Advanced Solutions existing bioprinting platform that helps life scientists overcome the challenges of reproducing consistent, complex organoid models at scale for drug development.

Available for sale across North America and Europe, this out-of-the-box offering of the BAB400 with our ImageXpress Cellular Imaging Systems enables turnkey automation of cell health monitoring and end-point assays.

Discover how the SpectraMax iD5 Multi-Mode Microplate Reader, which has an ultra-cool PMT for low background luminescence and high sensitivity can provide:

• Rapid assessment of cell viability in 3D cultures
• Highly sensitive luminescent readout
• Easy 3D cell culture and assay setup in U-bottom microplates

An increase in demand for faster high-throughput cell-line development and better screening in the pharmaceutical space is driving research facilities and companies to automate existing labs. Typical cell-line development requires the screening of tens of thousands of clones to find the best stable cells that yield high amounts of bioproducts.

In this application note, we discuss the automation of a mammalian cell-line development workflow the automated, integrated screening of transfected cells for edits, monoclonality, and growth assessment.

The growing demand for 3D cell culture and screening models can be limited by technical challenges for the effective handling, processing, and scaling of high-throughput applications. Many researchers have found success in meeting these challenges by implementing automation into their labs.

However, not all automated workflows are created equal. Effective solutions combine novel, cutting-edge technology with the ability to integrate existing instruments to create a customized system that works for the individual lab and their specific 2D and 3D applications.

Whether you are just starting to transition from 2D to 3D biology research, or looking for a fully automated organoid screening solution, we can help you build a personalized, product-agnostic, end-to-end automated workflow to deliver robust, reproducible results scale.